The Food and Drug Administration approved Novo Nordisk's Awiqli for children ages 10 and older with type 2 diabetes, Healio and the agency report. Awiqli is a once-weekly basal insulin. Healio says it is the first weekly basal option cleared for that age group. Labeling keeps diet and exercise as part of care.

Healio covers the pediatric expansion and notes earlier adult use. The FDA page is the record for the age range and weekly dosing. Novo Nordisk's own press note is not counted as a source here. Doctors still decide if a weekly shot fits a given child. Side effects and warnings stay on the FDA label.

Healio also notes that the pediatric nod rests on adult trial evidence plus a short study in teens and older children. The FDA said those younger patients absorbed the first dose in a pattern that supported extending the adult indication. Safety under age 10 is not established. The agency said Awiqli's safety profile is similar to other insulin products. Risks include low blood sugar, serious allergic reactions, and problems at the injection site.

Type 2 diabetes in youth is rising in the United States, and daily basal injections can be hard for families to keep up. A weekly schedule cuts basal shots from seven per week to one. That may help some households stick with treatment. List price and insurance coverage details were not the focus of the FDA notice. Parents should talk with a clinician before any switch from daily basal insulin.

What we know: The FDA cleared weekly Awiqli for children 10 and older with type 2 diabetes, alongside diet and exercise.
What we don't: How widely insurers will cover the pediatric use, and long-term outcomes in kids beyond the short study.